Amgen Inc (AMGN) operating KPIs
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)
Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%
Amgen stock Options Granted — Weighted-Average Grant-Date Fair Value ($/sh) ($)
Form 10-K Stock-Based Compensation Note (XBRL)
Latest, FY2025
62.76
Period ended Dec 31, 2025
Change on a year earlier
-9.5%
69.34 in FY2024
History
10 years
Since FY2016
Sources
7
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Stock Options Granted — Weighted-Average Grant-Date Fair Value ($/sh) ($) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 62.76 | -9.5% | Form 10-K (filed 2026-02-13) ↗ |
| FY2024 | Dec 31, 2024 | 69.34 | +65.6% | Form 10-K (filed 2026-02-13) ↗ |
| FY2023 | Dec 31, 2023 | 41.86 | -1.3% | Form 10-K (filed 2026-02-13) ↗ |
| FY2022 | Dec 31, 2022 | 42.43 | +4.9% | Form 10-K (filed 2025-02-14) ↗ |
| FY2021 | Dec 31, 2021 | 40.43 | -4.5% | Form 10-K (filed 2024-02-14) ↗ |
| FY2020 | Dec 31, 2020 | 42.34 | +39.0% | Form 10-K (filed 2023-02-09) ↗ |
| FY2019 | Dec 31, 2019 | 30.47 | -11.9% | Form 10-K (filed 2022-02-16) ↗ |
| FY2018 | Dec 31, 2018 | 34.60 | +25.6% | Form 10-K (filed 2021-02-09) ↗ |
| FY2017 | Dec 31, 2017 | 27.54 | 0.0% | Form 10-K (filed 2019-02-13) ↗ |
| FY2016 | Dec 31, 2016 | 27.55 | – | Form 10-K (filed 2019-02-13) ↗ |
Cite this data
StockData. (2026). Amgen Stock Options Granted — Weighted-Average Grant-Date Fair Value ($/sh) ($), annual FY2016–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/opt_grant_fv
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.